Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
309 studies found for:    nash
Show Display Options
RSS Create an RSS feed from your search for:
nash
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Withdrawn Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
Condition: Non-Alcoholic Steatohepatitis
Intervention:
2 Active, not recruiting Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo
3 Recruiting BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Condition: Non-Alcoholic Steatohepatitis
Interventions: Device: Suspected NASH BreathID test with 13C-Octanoate;   Device: Suspected NASH Breath test with 13C Methacetin
4 Unknown  Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)
Condition: Metabolic Parameters and Liver Histology
Interventions: Drug: Pioglitazone;   Drug: Pentoxifylline
5 Terminated
Has Results
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Steatohepatitis (NASH);   Hepatic Steatosis
Interventions: Drug: Omega-3-acid ethyl esters (Lovaza);   Drug: Placebo
6 Completed Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GR-MD-02;   Drug: Placebo
7 Recruiting Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)
Condition: NASH
Interventions: Drug: MT-3995;   Drug: Placebo
8 Recruiting A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: MSDC-0602K;   Drug: Placebo capsules
9 Not yet recruiting Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
Condition: Non-alcoholic Steatohepatitis (NASH)
Interventions: Drug: LMB763;   Drug: Placebo
10 Recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Condition: Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Drug: Elafibranor;   Drug: Placebo
11 Completed Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
Condition: Non-Alcoholic Steatohepatitis(NASH)
Interventions: Drug: Active treatment;   Drug: Placebo
12 Recruiting Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
Condition: NASH Related Decompensated Cirrhosis
Interventions: Drug: Fecal Microbiota Transplantation;   Drug: Standard Treatment;   Other: Weight Reduction
13 Active, not recruiting Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: GR-MD-02;   Drug: Placebo
14 Recruiting Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Condition: Non Alcoholic Steatohepatitis (NASH)
Interventions: Drug: Obeticholic Acid;   Drug: Placebo
15 Recruiting Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH
Condition: Non-alcoholic Fatty Liver Disease
Interventions: Biological: liver biopsy;   Biological: collection of stools;   Biological: blood sample
16 Completed Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Intervention: Drug: TRO19622
17 Active, not recruiting Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Condition: Hypertension, Portal
Interventions: Drug: GR-MD-02;   Drug: Placebo
18 Completed The Role of Leptin Receptors in NASH
Conditions: Nonalcoholic Steatohepatitis;   Metabolic Syndrome
Intervention: Other: no interventions, only regular blood-draw
19 Recruiting Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Conditions: Non-alcoholic Steatohepatitis;   Fibrosis;   Liver Diseases
Interventions: Drug: Emricasan (5 mg);   Drug: Emricasan (50 mg);   Drug: Placebo
20 Completed
Has Results
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Conditions: Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: obeticholic acid;   Drug: placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.